Search

U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)

Pulmonary Fibrosis

Pulmonary fibrosis is a condition leading to a build-up of scar tissue in the lungs. Over time, the lungs lose their ability to take in and transfer oxygen into the bloodstream.

FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD

Global Careers Page | Boehringer Ingelheim

Join a global team of more than 52,000 passionate and talented individuals dedicated to improving the health of humans and animals worldwide.

Get in touch

Duluth, Georgia

Boehringer Ingelheim Animal Health employs about

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis

AI-Driven Model Validated to Predict Risk of CKD Progression

Boehringer Ingelheim and Carelon Research conducted the first large-scale U.S. validation of a new AI-driven tool to predict the risk of CKD progression.

Our Businesses

How to Help Prevent Lyme Disease in Your Dog | Boehringer Ingelheim US

Click here to learn more about steps that pet owners can take to help prevent Lyme Disease in dogs.

Patient Centricity

New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF

Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients

Sustainable Development for Generations | Boehringer Ingelheim US

At BI, Sustainable Development – For Generations is about a journey. One that started in 1885 and one that we hope, and believe, will never end.

Protocols to Trim Mastitis in your Herd | Boehringer Ingelheim US

Read more on how the Boehringer Ingelheim mastitis grading chart protocols lead to creating better informed mastitis treatment decisions in livestock.

Results for Jardiance® (empaglifozin) | BI US

Read more about JARDIANCE, a significant reduction of risk for cardiovascular death or hospitalization for heart failure.

Central Data Science

Together with our business and IT colleagues, we develop data science-driven solutions, all the way from ideation to product.

Swine Vaccine Combo for Two Diseases | Boehringer Ingelheim US

Click here to read more on the launch of the Boehringer Ingelheim innovative vaccine combination, protecting US swine from two viruses in one shot.

Nick Gollop

Nick Gollop loves making a difference for patients and their families as a Senior Global Clinical Programme Leader in Clinical Development.

Translational Medicine & Clinical Pharmacology

We connect the right patient with the right drug on the right dosing schedule using data science methods from pharmacometrics to systems pharmacology.

Innovation in CNS Disease Research

Boehringer Ingelheim refocuses Gly-T1 inhibition brain research on schizophrenia

Open Innovation at Boehringer Ingelheim

Simon Manyara

Simon Manhara works with our culture and sustainability team towards making a positive social impact and creating a sustainable future.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers